Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials
Zhao, Ying Jiao
Khoo, Ai Leng
Soh, Lay Beng
Furukawa, Toshiaki A.
Lim, Boon Peng
MetadataShow full item record
CitationZhao, Ying Jiao, Liang Lin, Monica Teng, Ai Leng Khoo, Lay Beng Soh, Toshiaki A. Furukawa, Ross J. Baldessarini, Boon Peng Lim, and Kang Sim. 2016. “Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials.” BJPsych open 2 (1): 59-66. doi:10.1192/bjpo.bp.115.002576. http://dx.doi.org/10.1192/bjpo.bp.115.002576.
AbstractBackground: For treatment of patients diagnosed with schizophrenia, comparative long-term effectiveness of antipsychotic drugs to reduce relapses when minimising adverse effects is of clinical interest, hence prompting this review. Aims To evaluate the comparative long-term effectiveness of antipsychotic drugs. Method We systematically searched electronic databases for reports of randomised controlled trials (RCTs) of antipsychotic monotherapy aimed at reducing relapse risks in schizophrenia. We conducted network meta-analysis of 18 antipsychotics and placebo. Results: Studies of 10 177 patients in 56 reports were included; treatment duration averaged 48 weeks (range 4–156). Olanzapine was significantly more effective than chlorpromazine (odds ratio (OR) 0.35, 95% CI 0.14–0.88) or haloperidol (OR=0.50, 95% CI 0.30–0.82); and fluphenazine decanoate was more effective than chlorpromazine (OR=0.31, 95% CI 0.11–0.88) in relapse reduction. Fluphenazine decanoate, haloperidol, haloperidol decanoate and trifluoperazine produced more extrapyramidal adverse effects than olanzapine or quetiapine; and olanzapine was associated with more weight gain than other agents. Conclusions: Except for apparent superiority of olanzapine and fluphenazine decanoate over chlorpromazine, most agents showed intermediate efficacy for relapse prevention and differences among them were minor. Typical antipsychotics yielded adverse neurological effects, and olanzapine was associated with weight gain. The findings may contribute to evidence-based treatment selection for patients with chronic psychotic disorders. Declaration of interest R.J.B. received grants from the Bruce J. Anderson Foundation and the McLean Private Donors Psychopharmacology Research Fund. Copyright and usage © The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:29408187
- HMS Scholarly Articles